Revolution Medicines
RVMD
128 hedge funds and large institutions have $3.05B invested in Revolution Medicines in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 51 increasing their positions, 23 reducing their positions, and 20 closing their positions.
2,277% more call options, than puts
Call options by funds: $9.6M | Put options by funds: $404K
122% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 23
45% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 20
34% more capital invested
Capital invested by funds: $2.27B → $3.05B (+$775M)
8% more funds holding
Funds holding: 119 → 128 (+9)
4.05% more ownership
Funds ownership: 86.51% → 90.57% (+4.1%)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$165M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$72.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$66.9M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$46M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$67.3M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$15.4M |
| 3 |
PA
Perceptive Advisors
New York
|
-$8.88M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.28M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$7.93M |
RVMD Hedge Fund Activity: Q1 2021 in Review
128 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q1 2021, worth a combined $3.05B — up 34% from $2.27B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new RVMD positions and 20 closed out — a net gain of 9 holders — while 51 added to existing stakes and 23 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $165M. The largest seller was TRV GP III, cutting an estimated $67.3M.
- 128 institutional investors held Revolution Medicines (RVMD) as of Q1 2021, up from 119 in Q4 2020.
- Funds reported $3.05B of Revolution Medicines stock for Q1 2021, up 34% quarter-over-quarter.
- 29 funds opened new Revolution Medicines positions in Q1 2021 and 20 closed out, a net change of +9 holders.
- The largest Revolution Medicines buyer in Q1 2021 was Wellington Management Group, an estimated $165M added.
- The largest Revolution Medicines seller in Q1 2021 was TRV GP III, an estimated $67.3M sold.
Based on aggregated 13F filings for Q1 2021.